Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
Public ClinicalTrials.gov record NCT03515044. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
Study identification
- NCT ID
- NCT03515044
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Enrollment
- 71 participants
Conditions and interventions
Conditions
Interventions
- 40 mg Rifaximin SSD once daily Drug
- 40 mg Rifaximin SSD twice daily Drug
- 80 mg Rifaximin SSD once daily Drug
- 80 mg Rifaximin SSD twice daily Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 12, 2018
- Primary completion
- Mar 11, 2020
- Completion
- Mar 11, 2020
- Last update posted
- Apr 12, 2023
2018 – 2020
United States locations
- U.S. sites
- 34
- U.S. states
- 18
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bausch Health Site 18 | Corona del Mar | California | 92118 | — |
| Bausch Health Site 15 | Los Angeles | California | 90033 | — |
| Bausch Health Site 19 | Los Angeles | California | 90048 | — |
| Bausch Health Site 04 | San Francisco | California | 94143 | — |
| Bausch Health Site 13 | Bristol | Connecticut | 06010 | — |
| Bausch Health Site 08 | Miami | Florida | 33136 | — |
| Bausch Health Site 05 | Chicago | Illinois | 60611 | — |
| Bausch Health Site 33 | Iowa City | Iowa | 52242 | — |
| Bausch Health Site 03 | Boston | Massachusetts | 02215 | — |
| Bausch Health Site 07 | Detroit | Michigan | 48109 | — |
| Bausch Health 01 | Detroit | Michigan | 48127 | — |
| Bausch Health Site 25 | Tupelo | Mississippi | 38801 | — |
| Bausch Health Site 24 | St Louis | Missouri | 63104 | — |
| Bausch Health Site 27 | Newark | New Jersey | 07102 | — |
| Bausch Health Site 36 | Brooklyn | New York | 11215 | — |
| Bausch Health Site 09 | New York | New York | 10029 | — |
| Bausch Health Site 28 | New York | New York | 10065 | — |
| Bausch Health Site 17 | Cincinnati | Ohio | 45219 | — |
| Bausch Health Site 23 | Columbus | Ohio | 43210 | — |
| Bausch Health Site 11 | Philadelphia | Pennsylvania | 19104 | — |
| Bausch Health Site 26 | Philadelphia | Pennsylvania | 19107 | — |
| Bausch Health Site 10 | Philadelphia | Pennsylvania | 19141 | — |
| Bausch Health Site 12 | Pittsburgh | Pennsylvania | 15213 | — |
| Bausch Health Site 16 | Charleston | South Carolina | 29425 | — |
| Bausch Health Site 22 | Dallas | Texas | 75203 | — |
| Bausch Health Site 35 | Dallas | Texas | 75246 | — |
| Bausch Health Site 31 | Dallas | Texas | 75390 | — |
| Bausch Health Site 02 | Houston | Texas | 77001 | — |
| Bausch Health Site 37 | Houston | Texas | 77030 | — |
| Bausch Health Site 30 | Richmond | Virginia | 23226 | — |
| Bausch Health Site 06 | Richmond | Virginia | 23249 | — |
| Bausch Health Site 21 | Seattle | Washington | 98104 | — |
| Bausch Health Site 14 | Seattle | Washington | 98195 | — |
| Bausch Health Site 20 | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03515044, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03515044 live on ClinicalTrials.gov.